Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Business Wire
New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays of Variant Effect (MAVEs) studies to advance interpretation of hereditary cancer-linked genetic variants, published in Nature Communications. Led by researchers at Leiden University Medical Center in the Netherlands and supported by Ambry’s extensive clinical data, this study revealed previously unfounded missense pathogenicity in PALB2.PALB2 is one of the most clinically important genes associated with hereditary breast and pancreatic cancer. However, many PALB2 missense variants have remained difficult to interpret due to limited evidence and lack of support for missense
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield [Yahoo! Finance]Yahoo! Finance
- Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and YieldBusiness Wire
- Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones [Yahoo! Finance]Yahoo! Finance
- Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional BiomarkersBusiness Wire
TEM
Earnings
- 11/4/25 - Beat
TEM
Sec Filings
- 2/4/26 - Form 4
- 1/30/26 - Form 4
- 1/28/26 - Form 144
- TEM's page on the SEC website